Radiation Oncology

William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.

In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.

The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.

10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.

The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510(k) supported by the HYDROSPACE trial.

Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.

Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.

Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.

Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.

As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.

ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.

Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.

Sandra Turner, MBBS, PhD, shared ideas for radiation oncology teams to engage locally with World Radiotherapy Awareness Day.

“Far and away, a unified electronic health record is the single use case that could benefit both patients and physicians most, and AI has the potential to help us achieve that,” said Margarita Racsa, MD, MPH.

Sandra Turner, MBBS, PhD, outlined the global radiotherapy access gap stretching from Australia to sub-Saharan Africa.

How do we implement AI in a way that serves patients? Expert radiation oncologists discuss the crucial question.

Sandra Turner, MBBS, PhD, explained why September 7, radiotherapy’s first modern linac milestone, was chosen for World Radiotherapy Awareness Day.

Radiopharmaceutical therapy currently falls somewhere between localized treatment and systemic therapy, according to Mallika Marar, MD, MBA.

The regulatory decision for JBS-003 is intended to help guide personalized radiation de-escalation in patients with HPV-positive oropharyngeal cancer.

Rethinking dose fractions and managing subclinical renal and marrow toxicity represent ongoing challenges associated with the use of radiopharmaceutical therapy.

AI is intended to assist physicians, giving them more time for interpersonal engagement with patients, according to Nevine Hanna, MD, MPH, FACRO, DABR.

New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.

Josef Vymazal, MD, DSc, discusses a prospective study comparing delayed single- and double-dose gadopiclenol MRI for detecting small brain metastases.

Ayal Aizer, MD, MHS, describes an adaptive planning trial using synthetic CT to improve same-day treatment accuracy for anatomically unstable brain metastases.

Lizza Hendriks, MD, PhD, discussed why every patient with CNS metastases deserves a multidisciplinary team discussion.